In response, payers are introducing a number of cost-containment strategies, such as reducing healthcare budgets and implementing pricing and reimbursement cuts, as well as bolstering generic uptake. These measures, together with the increasingly tough regulatory environment, all have a negative impact on the pharmaceutical industry.
Branded pharmaceutical companies are set to lose approximately $100bn in sales due to the patent cliff and the resultant generic erosion of branded sales during 2010–15 in the seven major markets, while the industry is also feeling the effects of the recent global economic downturn both directly and indirectly.
Your key questions answered
* Evaluate factors driving healthcare costs in the developed and emerging markets, and how the economic downturn has impacted the healthcare landscape
* Gain insight into the impact that the patent cliff as well as growing use of biosimilars will have on branded pharma sales out to 2015
* Review the growing cost-containment and regulatory measures facing pharma, as well as the industry's response to grow profitability going forward
Strategic scoping and focus
DRIVERS OF RISING HEALTHCARE COSTS
Demographic trends in the major developed and emerging markets
Aging patient populations
Growing prevalence of chronic diseases
Greater use of expensive treatments – pharmaceutical expenditure is increasing in all markets
Expanding pubic healthcare coverage
IMPACT OF THE GLOBAL ECONOMIC DOWNTURN ON HEALTHCARE AND PHARMA
Impact of the economic downturn on both developed and emerging markets
Growing uninsured population – US patients are less able to cover the costs of healthcare, including pharmaceuticals
Government strategies to cut the budget deficit target he
Copyright©2010 PR Newswire.
All rights reserved